Last reviewed · How we verify
Prodiax-23
Prodiax-23 is a small molecule that targets the PI3K/AKT pathway.
Prodiax-23 is a small molecule that targets the PI3K/AKT pathway. Used for Phase 3 clinical trials for metastatic non-small cell lung cancer.
At a glance
| Generic name | Prodiax-23 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PI3K/AKT pathway, Prodiax-23 aims to reduce tumor growth and proliferation. This mechanism is being explored in the treatment of various cancers.
Approved indications
- Phase 3 clinical trials for metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients (PHASE4)
- Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
- Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |